Previous close | 14.00 |
Open | 13.70 |
Bid | 13.70 x N/A |
Ask | 13.80 x N/A |
Day's range | 13.70 - 13.70 |
52-week range | 9.85 - 24.20 |
Volume | |
Avg. volume | 3 |
Market cap | 1.171B |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | 13 May 2024 - 17 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Key Insights Significant control over Gyre Therapeutics by public companies implies that the general public has more...
Transformational Year with Strategic Shifts and Clinical Advances
Data readout from Phase 3 clinical trial in the People's Republic of China (“PRC”) evaluating F351 for the treatment of CHB-associated liver fibrosis expected by early 2025 U.S. Phase 2a clinical trial evaluating F351 for the treatment of NASH-associated liver fibrosis planned for 2025 Appointed Dr. Han Ying as Chief Executive Officer Acquired indirect controlling interest in Beijing Continent Pharmaceuticals Co., Ltd. (d/b/a Gyre Pharmaceuticals Co., Ltd) as part of business combination agreeme